Dr Reddy’s Laboratories has launched rivastigmine tartrate Capsules (1.5 mg, 3 mg, 4.5 mg and 6 mg), a bioequivalent generic version of Exelon capsules in the US market on September 15, 2011 following the approval by the United States Food & Drug Administration (USFDA) of the company’s Abbreviated New Drug Application (ANDA) for rivastigmine tartrate capsules.
The Exelon brand and generic rivastigmine tartrate had US sales of about $92.6 million for the most recent twelve months ending June 2011. Dr Reddy’s rivastigmine tartrate capsules 1.5 mg, 3 mg, 4.5 mg and 6 mg strengths are available in 60 count bottles.
Dr. Reddy's Laboratories is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |